These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8222499)

  • 21. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
    Sweet CS; Bradstreet DC; Berman RS; Jallard N; Saenz A; Weidler DJ
    Am J Hypertens; 1994 Dec; 7(12):1035-40. PubMed ID: 7702795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
    Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
    Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
    Mistry GC; Maes AL; Lasseter KC; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2008 May; 48(5):592-8. PubMed ID: 18353996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.
    Weber C; Birnböck H; Leube J; Kobrin I; Kleinbloesem CH; Van Brummelen P
    Br J Clin Pharmacol; 1993 Dec; 36(6):547-54. PubMed ID: 12959271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.
    Li Y; Li XH; Huang ZJ; Yang GP; Zhang GG; Zhao SP; Guo Y; Lu SJ; Ma JL; Meng FB; Chen P; Yuan H
    PLoS One; 2015; 10(2):e0117560. PubMed ID: 25693004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
    Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
    J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
    Lee HY; Kang HJ; Koo BK; Oh BH; Heung-Sun K; Kim KS; Seo HS; Ro YM; Kang JH; Woong CJ; Joo SJ; Kim MH; Joon-Han S; Yoon J; Park SH; Jin-Ok J; Ju AK; Chong-Yun R; Yeon KJ; Park KM; Lim DK; Park SY;
    Clin Ther; 2005 Jun; 27(6):728-39. PubMed ID: 16117979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.
    Kleinbloesem CH; Weber C; Fahrner E; Dellenbach M; Welker H; Schröter V; Belz GG
    Clin Pharmacol Ther; 1993 May; 53(5):585-92. PubMed ID: 8491068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
    Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
    Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial.
    Pathak L; Hiremath ; Kerkar PG; Manade VG
    J Assoc Physicians India; 2004 Mar; 52():197-202. PubMed ID: 15636308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.